David Cameron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Cameron has a total of 528 co-authors. Here are the top co-authors by number of shared publications:
- Aleix Prat
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
12 shared publications - Fabrice André
Gustave Roussy, Villejuif, France
12 shared publications - Agnes Lteif
15Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
11 shared publications - Ann H. Partridge
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA
11 shared publications - Astrid Thuerigen
14Novartis Pharma AG, Basel, Switzerland
11 shared publications - Denise Aysel Yardley
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
11 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Springer Nature in npj Breast Cancer
Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer
- 22 October 2026
- Published by Springer Nature in npj Breast Cancer
Open AccessResearch priorities to move ctDNA assays into clinical decision making in early-stage breast cancer
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Nodal Status And Patient-Reported Health Status Are Key Determinants Of Palbociclib Treatment Discontinuation In Early Breast Cancer: An Analysis From The PALLAS (AFT-05; ABCSG-42) Trial.Registrations: Clinicaltrials.Gov: NCT02513394, Eudract: 2014-005181-30
Background: In adjuvant HR+/HER2− breast cancer, tolerability and persistence with long-term therapy are critical. In PALLAS, adding palbociclib to endocrine therapy (ET) did not improve invasive disease-free or overall survival. We investigated factors associated with treatment intolerance and early discontinuation.Patients and methods: This exploratory analysis evaluated early palbociclib discontinuation among patients initiating planned two-year palbociclib plus ET in PALLAS. Competing-risks methods and cause-specific hazard models assessed associations between baseline demographic, clinical, and patient-reported outcome (PRO) measures and discontinuation for reasons other than recurrence or death. Dose reductions, treatment-emergent toxicities, and longitudinal PRO trajectories were also evaluated.Results: Among 2,840 patients initiating palbociclib plus ET, 1,171 (41.3%) discontinued palbociclib early. Dose reductions to 100 mg and 75 mg occurred in 55.2% and 33.6%, respectively. In multivariable analysis, higher nodal stage was associated with lower discontinuation risk (N3 versus N0: HR 0.59, 95% CI 0.45–0.79), whereas poor baseline overall quality of life (HR 1.87, 95% CI 1.10–3.19) and financial difficulties (HR 1.27, 95% CI 1.05–1.54) were independently associated with increased risk. Similar patterns were observed for dose reductions. Patients discontinuing within three months were older, less likely to have received chemotherapy, and had more baseline PRO impairments, particularly anxiety. Baseline PRO impairment was also associated with treatment-emergent toxicities, particularly non-haematological events. Longitudinally, fatigue and nausea were more prominent with palbociclib.Conclusions: Baseline patient-reported health status, nodal stage, and socioeconomic factors are important determinants of adjuvant palbociclib discontinuation. Integrating PROs into treatment decision-making and monitoring may help identify patients at increased risk of treatment intolerance and support more individualised management of prolonged adjuvant therapy.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNodal Status And Patient-Reported Health Status Are Key Determinants Of Palbociclib Treatment Discontinuation In Early Breast Cancer: An Analysis From The PALLAS (AFT-05; ABCSG-42) Trial.Registrations: Clinicaltrials.Gov: NCT02513394, Eudract: 2014-005181-30
Background: In adjuvant HR+/HER2− breast cancer, tolerability and persistence with long-term therapy are critical. In PALLAS, adding palbociclib to endocrine therapy (ET) did not improve invasive disease-free or overall survival. We investigated factors associated with treatment intolerance and early discontinuation.Patients and methods: This exploratory analysis evaluated early palbociclib discontinuation among patients initiating planned two-year palbociclib plus ET in PALLAS. Competing-risks methods and cause-specific hazard models assessed associations between baseline demographic, clinical, and patient-reported outcome (PRO) measures and discontinuation for reasons other than recurrence or death. Dose reductions, treatment-emergent toxicities, and longitudinal PRO trajectories were also evaluated.Results: Among 2,840 patients initiating palbociclib plus ET, 1,171 (41.3%) discontinued palbociclib early. Dose reductions to 100 mg and 75 mg occurred in 55.2% and 33.6%, respectively. In multivariable analysis, higher nodal stage was associated with lower discontinuation risk (N3 versus N0: HR 0.59, 95% CI 0.45–0.79), whereas poor baseline overall quality of life (HR 1.87, 95% CI 1.10–3.19) and financial difficulties (HR 1.27, 95% CI 1.05–1.54) were independently associated with increased risk. Similar patterns were observed for dose reductions. Patients discontinuing within three months were older, less likely to have received chemotherapy, and had more baseline PRO impairments, particularly anxiety. Baseline PRO impairment was also associated with treatment-emergent toxicities, particularly non-haematological events. Longitudinally, fatigue and nausea were more prominent with palbociclib.Conclusions: Baseline patient-reported health status, nodal stage, and socioeconomic factors are important determinants of adjuvant palbociclib discontinuation. Integrating PROs into treatment decision-making and monitoring may help identify patients at increased risk of treatment intolerance and support more individualised management of prolonged adjuvant therapy.
- Open Access
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Primary Analysis of the OPTIMA Phase III Randomised Non-Inferiority Trial of Test-Directed Chemotherapy in Patients With High Clinical Risk ER-Positive HER2-Negative Early Breast Cancer
Background: Evidence supporting tumour gene expression test use to assist adjuvant chemotherapy decisions in high-risk early breast cancer is limited. We investigated the safety of treatment decisions made using a 50-gene test in this population.Methods: OPTIMA [ISRCTN42400492], an international randomised trial, recruited patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes. Randomisation was performed centrally (1:1) between standard chemo-endocrine therapy and test-directed treatment; participants with a 50-gene tumour Risk of Recurrence (ROR) score >60 were allocated chemo-endocrine therapy whilst those with lower scores received endocrine therapy alone; for premenopausal women this included ovarian function suppression. The trial was analysed for non-inferiority of Invasive Breast Cancer Free Survival (IBCFS) in the per-protocol population with a 3% margin. Patients were recruited from 171 hospitals in 6 countries. Recruitment of an expanded premenopausal cohort is ongoing.Findings: 4429 patients underwent randomisation between January 16, 2017, and December 12, 2025; 4153 (93.8%) were included in the per-protocol analysis, 2059 in the control arm and 2094 in the test-directed arm. With 301 IBCFS events, the 5-year rate in the control arm was 91.8% [95% confidence interval (CI) 90.1-93.2%] and 90.3% [95% CI 88.5-91.8%] in the test-directed arm, adjusted hazard ratio (HR) 1.03 [90% CI 0.85-1.25], p(non-inferiority)=0.006. Similar results were seen in the 2779 (66.9%) per-protocol patient subgroup with ROR score ≤60 tumours (HR 1.06 [90% CI 0.81-1.40), p(non-inferiority]=0.003) and all other predefined subgroups including menopausal status, and lymph node and TNM stage and in the ITT population.Interpretation: The 50-gene test can be used to make safe adjuvant chemotherapy decisions, including for premenopausal women treated with ovarian function suppression and patients with high lymph node burden or stage IIIA disease. Funding UK National Institute for Health and Care Research Health Technology Assessment Programme and others.
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrimary Analysis of the OPTIMA Phase III Randomised Non-Inferiority Trial of Test-Directed Chemotherapy in Patients With High Clinical Risk ER-Positive HER2-Negative Early Breast Cancer
Background: Evidence supporting tumour gene expression test use to assist adjuvant chemotherapy decisions in high-risk early breast cancer is limited. We investigated the safety of treatment decisions made using a 50-gene test in this population.Methods: OPTIMA [ISRCTN42400492], an international randomised trial, recruited patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes. Randomisation was performed centrally (1:1) between standard chemo-endocrine therapy and test-directed treatment; participants with a 50-gene tumour Risk of Recurrence (ROR) score >60 were allocated chemo-endocrine therapy whilst those with lower scores received endocrine therapy alone; for premenopausal women this included ovarian function suppression. The trial was analysed for non-inferiority of Invasive Breast Cancer Free Survival (IBCFS) in the per-protocol population with a 3% margin. Patients were recruited from 171 hospitals in 6 countries. Recruitment of an expanded premenopausal cohort is ongoing.Findings: 4429 patients underwent randomisation between January 16, 2017, and December 12, 2025; 4153 (93.8%) were included in the per-protocol analysis, 2059 in the control arm and 2094 in the test-directed arm. With 301 IBCFS events, the 5-year rate in the control arm was 91.8% [95% confidence interval (CI) 90.1-93.2%] and 90.3% [95% CI 88.5-91.8%] in the test-directed arm, adjusted hazard ratio (HR) 1.03 [90% CI 0.85-1.25], p(non-inferiority)=0.006. Similar results were seen in the 2779 (66.9%) per-protocol patient subgroup with ROR score ≤60 tumours (HR 1.06 [90% CI 0.81-1.40), p(non-inferiority]=0.003) and all other predefined subgroups including menopausal status, and lymph node and TNM stage and in the ITT population.Interpretation: The 50-gene test can be used to make safe adjuvant chemotherapy decisions, including for premenopausal women treated with ovarian function suppression and patients with high lymph node burden or stage IIIA disease. Funding UK National Institute for Health and Care Research Health Technology Assessment Programme and others.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S28 from Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Supplementary Figure 1. Clustered heatmap of binary distance across callers. Supplementary Figure 2. Flow diagram of gene fusion calling, validation and filtering process of number of fusions and number of patients. Barplots refers to within-sample validation rate Supplementary Figure 3. Upset plot showing molecular data available. Supplementary Figure 4. Tumor purity in samples with detected or undetected gene fusions. Supplementary Figure 5. Number of gene fusions in primary and metastatic samples across the different sites of metastases. Supplementary Figure 6. Frequency of totally or partially retained or lost kinase domain. Supplementary Figure 7. Number of fusions in primary and metastatic samples, for the different sites of metastasis and across the different IHC subtypes Supplementary Figure 8. Tumor purity in metastatic versus primary samples, and the number of lost and acquired fusions. Supplementary Figure 9. Number of fusions in primary and metastatic samples, and the number of acquired and lost gene fusions versus type of adjuvant treatment for ER+/HER2-. Supplementary Figure 10. Enrichment of hallmark mitotic spindle for genes involved in shared, lost and acquired fusions. Supplementary Figure 11. Recurrent acquired gene fusions. Supplementary Figure 12. Protein domains of recurrent 5’ and 3’ genes involved in fusions acquired in metastasis of patients with paired samples. Supplementary Figure 13. Protein domains retention in fusions involving ESR1 detected in metastatic samples and ESR1 gene expression in corresponding samples. Supplementary Figure 14. Correlation between the cytoband wise gene fusion and CN gain frequency for the different subtypes. Supplementary Figure 15. Frequency plot (cytoband-wise) of gene fusions for shared and acquired gene fusions detected in paired samples. Supplementary figure 16. Fraction of CN loss, neutral and gain events for fused genes. Supplementary Figure 17. Fusions detected in primary and metastatic samples for TP53 and PIK3CA mutated and wild-type across the different IHC subtypes Supplementary figure 18. Shared, lost and acquired fusions detected in primary adn metastatic samples for TP53 and PIK3CA mutated and wild-type across the different IHC subtypes Supplementary figure 19. Bar plots showing the frequency of samples with fusions involving ESR1 (orange) and not (light grey) from primary, metastatic, and paired primary/metastatic samples from recurrent ER+ patients Supplementary figure 20. Number of fusions in HRD score low and high primary samples Supplementary figure 21. Number of fusions in HRD score low and high primary samples across subtypes Supplementary Figure 22. Delta mutational load in paired metastatic vs primary samples versus the number of acquired gene fusions. Supplementary Figure 23. Delta mutational load in paired metastatic vs primary samples versus the number of acquired gene fusions across subtypes Supplementary Figure 24. Number of fusions versus the values of the CX signatures for primary samples from the AURORA dataset. Supplementary Figure 25. Number of fusions versus the values of the CX signatures for metastatic samples Supplementary Figure 26. Number of fusions versus the values of the CX signatures for samples from TCGA-BRCA dataset. Supplementary Figure 27. Frequency of intra-chromosomal fusions involving genes mapping to the same topologically associating domains (TAD) versus not across breast cancer subtypes for primary and metastatic samples from the AURORA dataset and for samples from the TCGA-BRCA dataset Supplementary Figure 28. Frequency of intra-chromosomal fusions involving genes mapping to the same topologically associating domains (TAD) versus not in metastatic samples across breast cancer subtypes for recurrent and de novo patients
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S28 from Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Supplementary Figure 1. Clustered heatmap of binary distance across callers. Supplementary Figure 2. Flow diagram of gene fusion calling, validation and filtering process of number of fusions and number of patients. Barplots refers to within-sample validation rate Supplementary Figure 3. Upset plot showing molecular data available. Supplementary Figure 4. Tumor purity in samples with detected or undetected gene fusions. Supplementary Figure 5. Number of gene fusions in primary and metastatic samples across the different sites of metastases. Supplementary Figure 6. Frequency of totally or partially retained or lost kinase domain. Supplementary Figure 7. Number of fusions in primary and metastatic samples, for the different sites of metastasis and across the different IHC subtypes Supplementary Figure 8. Tumor purity in metastatic versus primary samples, and the number of lost and acquired fusions. Supplementary Figure 9. Number of fusions in primary and metastatic samples, and the number of acquired and lost gene fusions versus type of adjuvant treatment for ER+/HER2-. Supplementary Figure 10. Enrichment of hallmark mitotic spindle for genes involved in shared, lost and acquired fusions. Supplementary Figure 11. Recurrent acquired gene fusions. Supplementary Figure 12. Protein domains of recurrent 5’ and 3’ genes involved in fusions acquired in metastasis of patients with paired samples. Supplementary Figure 13. Protein domains retention in fusions involving ESR1 detected in metastatic samples and ESR1 gene expression in corresponding samples. Supplementary Figure 14. Correlation between the cytoband wise gene fusion and CN gain frequency for the different subtypes. Supplementary Figure 15. Frequency plot (cytoband-wise) of gene fusions for shared and acquired gene fusions detected in paired samples. Supplementary figure 16. Fraction of CN loss, neutral and gain events for fused genes. Supplementary Figure 17. Fusions detected in primary and metastatic samples for TP53 and PIK3CA mutated and wild-type across the different IHC subtypes Supplementary figure 18. Shared, lost and acquired fusions detected in primary adn metastatic samples for TP53 and PIK3CA mutated and wild-type across the different IHC subtypes Supplementary figure 19. Bar plots showing the frequency of samples with fusions involving ESR1 (orange) and not (light grey) from primary, metastatic, and paired primary/metastatic samples from recurrent ER+ patients Supplementary figure 20. Number of fusions in HRD score low and high primary samples Supplementary figure 21. Number of fusions in HRD score low and high primary samples across subtypes Supplementary Figure 22. Delta mutational load in paired metastatic vs primary samples versus the number of acquired gene fusions. Supplementary Figure 23. Delta mutational load in paired metastatic vs primary samples versus the number of acquired gene fusions across subtypes Supplementary Figure 24. Number of fusions versus the values of the CX signatures for primary samples from the AURORA dataset. Supplementary Figure 25. Number of fusions versus the values of the CX signatures for metastatic samples Supplementary Figure 26. Number of fusions versus the values of the CX signatures for samples from TCGA-BRCA dataset. Supplementary Figure 27. Frequency of intra-chromosomal fusions involving genes mapping to the same topologically associating domains (TAD) versus not across breast cancer subtypes for primary and metastatic samples from the AURORA dataset and for samples from the TCGA-BRCA dataset Supplementary Figure 28. Frequency of intra-chromosomal fusions involving genes mapping to the same topologically associating domains (TAD) versus not in metastatic samples across breast cancer subtypes for recurrent and de novo patients
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Supplementary Table 1 Overview of patients’ and disease’s characteristics of AURORA gene fusion project Supplementary Table 2 AURORA gene fusion catalog Supplementary Table 3 Gene fusions involving ESR1 as 5 or 3 prime partner Supplementary Table 4 Clinical characteristics of patients with ESR1 fusions Supplementary Table 5 Frequency of fusions by cytoband Supplementary Table 6 Results of the Spearman's correlation test between the number of fusions and Gene Expression signatures levels
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Supplementary Table 1 Overview of patients’ and disease’s characteristics of AURORA gene fusion project Supplementary Table 2 AURORA gene fusion catalog Supplementary Table 3 Gene fusions involving ESR1 as 5 or 3 prime partner Supplementary Table 4 Clinical characteristics of patients with ESR1 fusions Supplementary Table 5 Frequency of fusions by cytoband Supplementary Table 6 Results of the Spearman's correlation test between the number of fusions and Gene Expression signatures levels
- 22 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 947-962
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Purpose: Gene fusions are molecular rearrangements with oncogenic potential. However, their role in disease progression and therapy resistance remains largely unexplored, particularly in breast cancer. Experimental Design: In this study, we utilized multiomics data from the AURORA program to characterize gene fusions in metastatic breast cancer. We analyzed RNA sequencing data from 325 primary tumors and 350 metastatic lesions across 476 patients to develop a high-confidence catalog of gene fusions. Results: In a subset of 398 matched samples from 199 patients, we observed a higher burden of gene fusions in metastatic tumors compared with their corresponding primary tumors. Metastatic-specific (acquired) gene fusions were characterized by few recurrent rearrangements and were generally absent in patients with de novo metastatic disease. We observed a colocalization of gene fusions with subtype-specific copy-number gains. Various scores indicative of genomic instability were found to be associated with the gene fusion burden. Fusions involving genes located within the same topologically associating domain (TAD) were common in HER2-positive tumors and frequently acquired in metastatic triple-negative breast cancer. The presence of gene fusions, particularly those that were acquired or involved in genes within the same TAD, was associated with poor prognosis in estrogen receptor–positive/HER2-negative tumors. Patients with acquired ESR1 fusions exhibited a more aggressive disease course, characterized by shorter treatment response and poorer clinical outcomes. Conclusions: The AURORA gene fusion catalog may serve as a valuable resource for identifying targetable genetic alterations, thereby supporting the development of more effective therapeutic strategies for breast cancer.
- 22 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 947-962
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
Purpose: Gene fusions are molecular rearrangements with oncogenic potential. However, their role in disease progression and therapy resistance remains largely unexplored, particularly in breast cancer. Experimental Design: In this study, we utilized multiomics data from the AURORA program to characterize gene fusions in metastatic breast cancer. We analyzed RNA sequencing data from 325 primary tumors and 350 metastatic lesions across 476 patients to develop a high-confidence catalog of gene fusions. Results: In a subset of 398 matched samples from 199 patients, we observed a higher burden of gene fusions in metastatic tumors compared with their corresponding primary tumors. Metastatic-specific (acquired) gene fusions were characterized by few recurrent rearrangements and were generally absent in patients with de novo metastatic disease. We observed a colocalization of gene fusions with subtype-specific copy-number gains. Various scores indicative of genomic instability were found to be associated with the gene fusion burden. Fusions involving genes located within the same topologically associating domain (TAD) were common in HER2-positive tumors and frequently acquired in metastatic triple-negative breast cancer. The presence of gene fusions, particularly those that were acquired or involved in genes within the same TAD, was associated with poor prognosis in estrogen receptor–positive/HER2-negative tumors. Patients with acquired ESR1 fusions exhibited a more aggressive disease course, characterized by shorter treatment response and poorer clinical outcomes. Conclusions: The AURORA gene fusion catalog may serve as a valuable resource for identifying targetable genetic alterations, thereby supporting the development of more effective therapeutic strategies for breast cancer.
- Top Cited PapersOpen Access
- 8 October 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4205-4213
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
In DESTINY-Breast04 (NCT03734029), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55–0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55–0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%–10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029.
- 8 October 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4205-4213
Top Cited PapersOpen AccessTrastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
In DESTINY-Breast04 (NCT03734029), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55–0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55–0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%–10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029.
- Open Access
- 12 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2317-2326
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
Background: The ability to predict ovarian function loss after anticancer treatment is important for appropriate oncofertility counseling and to aid in therapy decision-making for young women with early breast cancer (eBC). Methods: This biomarker analysis of the BETH (NCT00625898) and KAITLIN (NCT01966471) randomized trials investigated anti-Müllerian hormone (AMH) use, alone and combined with follicle stimulating hormone (FSH) and estradiol (E2), for predicting ovarian function loss following currently adopted chemotherapy and anti-HER2 therapy in premenopausal women with HER2-positive eBC. Serum samples were centrally tested measuring AMH, FSH, and E2 using Roche Elecsys assays. Results: Among 194 included patients (BETH: n = 62; KAITLIN: n = 132), AMH values declined from baseline median 8.44 pmol L−1 to undetectable levels (<0.07 pmol L−1) at the end of therapy, with partial recovery at 36 months (median 0.14 pmol L−1). AMH measured at baseline was predictive of ovarian loss (area under the ROC curve [AUC] = 0.784). Addition of age to AMH slightly improved AUC to 0.800. AMH measured at the end of therapy had AUC 0.741, which increased to 0.785 with addition of age. The combination of AMH at baseline and end of therapy increased prediction to 0.808 and with addition of age to 0.820. Addition of baseline FSH and E2 did not improve prediction in any analysis. Conclusions: These results support the use of pretreatment measurement of AMH in predicting ovarian function loss in premenopausal women with HER2-positive eBC receiving chemotherapy and anti-HER2 therapy. Measurement of AMH at the end of treatment had reduced accuracy than pretreatment but in combination added slightly to the value of pretreatment sampling.
- 12 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2317-2326
Open AccessPredicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
Background: The ability to predict ovarian function loss after anticancer treatment is important for appropriate oncofertility counseling and to aid in therapy decision-making for young women with early breast cancer (eBC). Methods: This biomarker analysis of the BETH (NCT00625898) and KAITLIN (NCT01966471) randomized trials investigated anti-Müllerian hormone (AMH) use, alone and combined with follicle stimulating hormone (FSH) and estradiol (E2), for predicting ovarian function loss following currently adopted chemotherapy and anti-HER2 therapy in premenopausal women with HER2-positive eBC. Serum samples were centrally tested measuring AMH, FSH, and E2 using Roche Elecsys assays. Results: Among 194 included patients (BETH: n = 62; KAITLIN: n = 132), AMH values declined from baseline median 8.44 pmol L−1 to undetectable levels (<0.07 pmol L−1) at the end of therapy, with partial recovery at 36 months (median 0.14 pmol L−1). AMH measured at baseline was predictive of ovarian loss (area under the ROC curve [AUC] = 0.784). Addition of age to AMH slightly improved AUC to 0.800. AMH measured at the end of therapy had AUC 0.741, which increased to 0.785 with addition of age. The combination of AMH at baseline and end of therapy increased prediction to 0.808 and with addition of age to 0.820. Addition of baseline FSH and E2 did not improve prediction in any analysis. Conclusions: These results support the use of pretreatment measurement of AMH in predicting ovarian function loss in premenopausal women with HER2-positive eBC receiving chemotherapy and anti-HER2 therapy. Measurement of AMH at the end of treatment had reduced accuracy than pretreatment but in combination added slightly to the value of pretreatment sampling.
- 7 May 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1745-1746
Response to Li, Liu, Duan, et al.
- 7 May 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1745-1746
Response to Li, Liu, Duan, et al.
- Open Access
- 18 October 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (3) , 486-495
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis
There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed to identify low risk cancers where RT will not further reduce recurrence rates. An individual participant data meta-analysis was performed in 623 cases of node-negative ER+/HER2-negative early breast cancer enrolled in three RT randomized trials for whom primary tumor material was available for analysis. A Cox proportional hazards model on time to locoregional recurrence (LRR) was used to test the interaction between POLAR score and RT. 429 (69%) patients’ tumors had a high POLAR score and 194 (31%) had a low score. Patients with high POLAR score had, in the absence of RT, a 10-year cumulative incidence of LRR: 20% (15%-26%) vs 5% (2%-11%) for those with a low score. Patients with a high POLAR score had a large benefit from RT (hazard ratio [HR] for RT vs no RT: 0.37 [0.23-0.60], p < .001). In contrast, there was no evidence of benefit from RT for patients with a low POLAR score (HR: 0.92 [0.42-2.02], p = .832). The test for interaction between RT and POLAR was statistically significant (p = .022). POLAR is not only prognostic for locoregional recurrence but also predictive of benefit from radiotherapy in selected patients. Patients ≥ 50 years with ER+/HER2-negative disease and a low POLAR score could consider omitting adjuvant RT. Further validation in contemporary clinical cohorts is required.
- 18 October 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (3) , 486-495
Open AccessValidation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis
There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed to identify low risk cancers where RT will not further reduce recurrence rates. An individual participant data meta-analysis was performed in 623 cases of node-negative ER+/HER2-negative early breast cancer enrolled in three RT randomized trials for whom primary tumor material was available for analysis. A Cox proportional hazards model on time to locoregional recurrence (LRR) was used to test the interaction between POLAR score and RT. 429 (69%) patients’ tumors had a high POLAR score and 194 (31%) had a low score. Patients with high POLAR score had, in the absence of RT, a 10-year cumulative incidence of LRR: 20% (15%-26%) vs 5% (2%-11%) for those with a low score. Patients with a high POLAR score had a large benefit from RT (hazard ratio [HR] for RT vs no RT: 0.37 [0.23-0.60], p < .001). In contrast, there was no evidence of benefit from RT for patients with a low POLAR score (HR: 0.92 [0.42-2.02], p = .832). The test for interaction between RT and POLAR was statistically significant (p = .022). POLAR is not only prognostic for locoregional recurrence but also predictive of benefit from radiotherapy in selected patients. Patients ≥ 50 years with ER+/HER2-negative disease and a low POLAR score could consider omitting adjuvant RT. Further validation in contemporary clinical cohorts is required.